Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Valion Bio, Inc. (VBIO)

Valion Bio CFO, COO and President Lisa Wolf to resign effective December 11, 2026

Negative Impact 4 of 5 leadership Written later

Valion Bio, Inc. disclosed that Lisa Wolf, its President, Chief Operating Officer and Chief Financial Officer, has voluntarily resigned from all three roles, with the resignation effective December 11, 2026. The filing does not state a reason or name a successor, so shareholders will need to watch for a replacement announcement.

Key points

  • Lisa Wolf notified the Special Committee of the Board on October 31, 2026.
  • Her resignation covers the positions of President, Chief Operating Officer and Chief Financial Officer.
  • The resignation takes effect December 11, 2026, and had not yet taken effect as of the filing date.

The filing

CompanyValion Bio, Inc. (VBIO)
Form8-K, current report
Filed with the SECNov 5, 2026, 4:15 PM ET
Accession number0001683168-26-008352

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.